Clinical Trials

DNX-2401 + Pembrolizumab for Recurrent Glioblastoma

Actively recruiting

Study 2401BT-002P (CAPTIVE) is a Phase 2 trial being conducted in collaboration with Merck to evaluate the efficacy and safety of DNX-2401 in combination with pembrolizumab (KEYTRUDA), Merck’s anti-PD-1 therapy. Adult subjects diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.

learn more about CAPTIVE >

DNX-2401 for Pediatric Patients with Newly Diagnosed Pontine Glioma

Actively Recruiting

Study D24-DIPG is a Phase 1 trial to evaluate the safety and efficacy of DNX-2401 in pediatric patients. Patients who are less than 18 years old with newly diagnosed diffuse intrinsic pontine glioma may be eligible. 

learn more about D24-DIPG at www.clinicaltrials.gov >

DNX-2440 for Recurrent Glioblastoma

Actively Recruiting

Study D2440GBM1 is a Phase 1 trial being conducted at Clinica Universidad de Navarra (Spain) to evaluate the safety and efficacy of DNX-2440. Adult subjects  with diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.

learn more about D2440GBM1 at www.clinicaltrials.gov >

learn more about all DNAtrix clinical trials at www.clinicaltrials.gov >

 

Expanded Access/Compassionate Use: 

At this time, DNAtrix does not offer expanded access or compassionate use programs for investigational agents under development.  We evaluate the need on a continuous basis.


Virus artwork by Luke Jerram